GE is backing a partnership between Quibim and other molecular imaging partners.
GE Healthcare is backing a molecular imaging partnership between artificial intelligence (AI) and medical image processing company Quibim and several other molecular imaging partners to create a total-body PET/CT scanner for simultaneous whole-body imaging.
This $8.9-million project includes Full Body Insight, a total-body PET technologies company, and Oncovision, a molecular imaging equipment specialist, and it is partially funded by the Valencia Government Health Project in Spain.
According to project leaders, this High Sensitivity Molecular Imaging Project is designed to develop new PET applications for biomedical research. The goal is to increase axial coverage to improve sensitivity to enable dose reduction and truncate acquisition time without degrading image quality. These advancements will directly benefit pediatric patients, as well as those who need repeated scanning, project representatives said.
In addition, improvements to axial coverage will also enable dynamic acquisitions of main organs, project leaders said.
Quibim’s role, according to company representatives, is to provide whole-body segmentation to perform automatic quantification of PET images.
“We will create automatic pipelines to obtain a virtual in vivo dissection of key organs using AI and characterize radiotracer and radiomics features,” said Angel Alberich-Bayarri, Quibim’s chief executive officer and co-founder. “The output of this innovative collaboration will help clinicians reading a PET exam decide on which regions they must focus on to support patient diagnosis and prognosis evaluations.”
Project leaders anticipate the prototype system will be available in 2023.
Could Virtual Non-Contrast Images from Photon-Counting CT Reduce Radiation Dosing with CCTA?
March 28th 2024Emerging research on coronary artery calcium scoring for the assessment of coronary artery disease (CAD) suggests the use of virtual non-contrast images from photon-counting CT may lead to a nearly 20 percent reduction in radiation dosing.
FDA Clears CT-Based AI Tools for PE Detection and Stroke Severity Assessment
March 26th 2024The artificial intelligence (AI) modalities CINA-iPE and CINA-ASPECTS may facilitate improved detection of incidental pulmonary embolism and stroke evaluation, respectively, based on computed tomography (CT) scans.
FDA Clears Remote Scanning Support Platform for MRI, CT and PET/CT
March 25th 2024The multimodality system nCommand Lite reportedly facilitates real-time remote imaging guidance on scanning parameters and procedure assessments to licensed technologists for a variety of imaging modalities including CT and MRI.
FDA Clears Mobile C-Arm Device that May Accelerate Fluoroscopic and 3D CT Imaging
March 21st 2024Offering ease of mobility and self-driving capabilities, the Ciartic Move C-arm device reportedly reduces the stress and potential for error associated with manual repositioning during intraoperative imaging with computed tomography and fluoroscopy.